Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

TxCell (France), a clinical-stage biotechnology developing cell-based immunotherapies for chronic inflammatory and neurological diseases, closed a $15.9M Series C financing. Participants include CDC Entreprises, Auriga Partners and Seventure Partners. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP […]

Gliknik (Baltimore, MD), a clinical-stage biotechnology company focused on treatments for cancer and autoimmune diseases, closed a $4.9M Series B financing. Participants include Baxter Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.

Innavirvax (France), a biopharmaceutical company focused on therapeutic solutions of pathologies associated with immune deregulation, closed a $4.9M Series B financing. Participants include Pradeyrol Développement, Fa Dièse, CapDecisif Management and FRCI.

Telormedix (Switzerland) a clinical-stage biopharmaceutical company focused on Toll-like receptor agonists for bladder cancer and autoimmune disease, closed a $8.3M Series B financing. Participants include Aravis Venture and Proquest Investments.

Probiodrug (Germany) a clinical-stage biopharmaceutical company focused enzyme inhibitors for Alzheimer’s and inflammatory disease, closed a $20M Series C financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Sciences Partners, Biogen Idec New Ventures, TVM Capital, HBM BioVentures, Goodvent and Wellington Management Company.

Selecta Biosciences (Watertown, MA) a clinical-stage biopharmaceutical company focused on a new class of vaccines and immunotherapies for nicotine addiction, cancer, diabetes, influenza and human papilloma virus (HPV) closed a $47.25M Series D financing. Participants include Rusnano.

Provenance Biopharmaceuticals (Waltham, MA) a clinical-stage biopharmaceutical company focused on monoclonal antibody therapy for non-Hodgkins lymphoma and other hematological cancers, closed a $8M Series A financing. Participants include Alopexx Enterprises.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock. The 2Q11 OnBioVC Trend Analysis will […]

Anergis (Switzerland) a clinical-stage biopharmaceutical company focused on immunotherapies against allergies, closed announced today that it has closed a $14.3M Series A financing. Participants include Vinci Capital, BioMedInvest, Sunstone Capital, Esperante Ventures and Initiative Capital Romandie.

DBV Technologies (France) a clinical-stage drug:device biopharma company focused on non invasive immunotherapy delivery for food allergies, closed a $25.5M Series C financing. Participants include InnoBio Fund, Lundbeckfond Ventures, ALTO Invest, Sofinnova Partners, ALK Abello and Apax Partners.

Vaximm (Switzerland) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for various solid tumors, closed a $8M Series B financing. Participants include BB Biotech Ventures, Sunstone Capital, Merck Serono Ventures and BioMedPartners.

Kite Pharma (Los Angeles, CA) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for renal cell carcinoma and hepatocellular carcinoma, closed a $15M Series A financing. Participants include TPG Capital.

« Previous Entries  Next Page »

to top of page...